MAP2K7 and cancer: Similarly, in preclinical models of pancreatic cancer and lung cancer, inhibition of MAPK1 expression by siRNA or MAPK1 activity by MEK inhibitors sensitized specific cancer cell lines to erlotinib [25, 26].